In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) plus chemotherapy for patients with advanced (stage 3 – 4) Hodgkin’s lymphoma (HL). This study concluded that this treatment is effective for these patients. Some background The most commonly used frontline chemotherapy regimen for advanced HL...
Read More
In 1904, a physician wrote about a patient with leukemia who went into remission when he got the flu. Though the patient was not cured, it was a ray of hope at a time when there were no treatments for leukemia. Other cases were reported throughout the years of people with Burkitt’s Lymphoma and Hodgkin’s Lymphoma going into remission when they...
Read MoreIn a nutshell This trial will investigate the effects of different combinations of anti-cancer drugs in patients with pediatric Hodgkin lymphoma (HL). The main outcomes measured will be how fast a patient responds to therapy and also survival in general, and without cancer returning or getting worse. The trial is recruiting in Memphis, Tennessee,...
Read MoreIn a nutshell This study looked at the changes in the sense of taste of children with cancer and those who received a stem cell transplant. Researchers found that taste changes in these patients were common. Some background Cancer is often treated with powerful drugs or stem cell transplant. These may have strong side effects. In...
Read More
In a nutshell This study examined how safe and effective brentuximab vedotin (Adcedris) is when added to conventional treatments for relapsed and unresponsive Hodgkin lymphoma. This study concluded that this treatment is safe and effective when used as part of the treatment for Hodgkin lymphoma. Some background Standard treatment for...
Read More
In a nutshell This article reviews treatment strategies for patients with early-stage (stage 1 – 2) Hodgkin lymphoma (HL). Some background One of the main treatment goals for patients with HL is to improve long-term outcomes. However, many patients experience complications decades after initial treatment. These may include secondary cancer...
Read More
In a nutshell This study examined the safety and effectiveness of sintilimab in patients with relapsed or unresponsive Hodgkin lymphoma. This study concluded that sintilimab could be a new treatment option for these patients. Some background Hodgkin disease (HD) is a type of lymphoma. In patients who relapse or do not respond to first-line...
Read More
In a nutshell This trial is examining the effectiveness of a new treatment combination for advanced Hodgkin’s lymphoma (HL). The main outcomes to be measured will be the number of patients who experience side effects and response to treatment. This study is being conducted in New York, New Jersey, and Ohio, the United States. The details The...
Read More
During July and early August of 2018, the Harris Poll in association with the American Society of Clinical Oncologists (ASCO’s) conducted a poll of 4,887 U.S. adults, 1001 of these have or had cancer. This second annual National Cancer Opinion Survey explored a wide range of topics. The findings clearly describe disparities in the care patients with...
Read More
In a nutshell This study reviewed how the research on pediatric and adult Hodgkin lymphoma (HL) could be applied to adolescent HL. The main finding was that treatments for pediatric and adult HL have similar effects in adolescent HL. Some background About 8500 people are diagnosed with HL in the US each year. There are 2 main types of HL:...
Read More
In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...
Read More
In a nutshell This study investigated the effects of adding lenalidomide (Revlimid) to doxorubicin (Adriamycin), vinblastine (Velban), and dacarbazine (DTIC-Dome) treatment for older patients with Hodgkin lymphoma (HL). The main finding was that this combination is effective but severe side-effects may be experienced. Some background HL is a cancer...
Read More
